Liver News and Research

RSS

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

15 Apr 2015

Sanofi introduces new probiotic supplement for children in South Korea

Sanofi launches a new probiotic supplement for kids in South Korea. Released, in Costco stores under the global Cenovis Kids brand, the new supplement with a delicious vanilla flavor and teddy bear shape is produced by Anlit Ltd., Israel, and designed specifically for kids.

14 Apr 2015

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment.

13 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

New data support use of Exalenz Bioscience's BreathID test for diagnosing H. pylori infection

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced new published data supporting the use of the Company's point-of-care BreathID urea breath test for diagnosing Helicobacter pylori infection (H. pylori) in the emergency department (ED) setting.

13 Apr 2015

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

A new study finds that effective new hepatitis C drugs are so expensive the state of Rhode Island would have to spend almost twice its entire prison health budget to treat all its chronically infected inmates.

10 Apr 2015

New, cross-sector collaboration aims to discover clinical biomarker for pancreatic cancer

The search to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer is at the foundation of a new, cross-sector collaboration. Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach; the Cancer Center at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, and the Pancreatic Cancer Research Team managed by Cancer Research And Biostatistics announced today they will work together to eradicate the disease.

9 Apr 2015

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Shire plc today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not meet the primary or secondary endpoints in the study of 20 pediatric patients with Alagille syndrome (ALGS), a rare, life-threatening genetic disorder that presents with chronic cholestasis (accumulation of bile acids in the liver) and severe pruritus (itching).

9 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

Study: Standard nursing assessments may help improve outcomes in cirrhosis patients

Patients hospitalized with advanced cirrhosis, a chronic and degenerative disease of the liver, are at increased risk of death. The tools currently used to assess that risk are limited in predicting which patients will need a liver transplant and which will be healthy enough to survive transplantation.

8 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

Exercise benefits obese, overweight people with NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the western world. A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with NAFLD.

8 Apr 2015

Two case studies provide potential new avenue for treatment of kidney cancer

UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of kidney cancer.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

New model can help predict how humans adapt to high- and low-altitude hypoxia

There are few times in life when one should aim for suboptimal performance, but new research at Rice University suggests scientists who study metabolism and its role in evolution should look for signs of just that.

7 Apr 2015

UC Davis researchers unravel how micro RNA could potentially lead to novel cancer therapies

The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets?

6 Apr 2015

Nanomedicine strategy can help reduce heart attacks, strokes

A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.

6 Apr 2015

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.

3 Apr 2015

New resource available to help older Chinese Americans better understand their healthcare needs

On the eve of National Minority Health Month, which helps raise awareness for disparities in health and care among minorities in the U.S., a new resource is available to help one such group, older Chinese Americans, better understand and drive their own well-being.

3 Apr 2015

NASH patients more likely to have increased intestinal permeability, shows study

Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

3 Apr 2015

Liver News and Research

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Sanofi introduces new probiotic supplement for children in South Korea

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

New data support use of Exalenz Bioscience's BreathID test for diagnosing H. pylori infection

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

New, cross-sector collaboration aims to discover clinical biomarker for pancreatic cancer

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Study: Standard nursing assessments may help improve outcomes in cirrhosis patients

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Exercise benefits obese, overweight people with NAFLD

Two case studies provide potential new avenue for treatment of kidney cancer

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

New model can help predict how humans adapt to high- and low-altitude hypoxia

UC Davis researchers unravel how micro RNA could potentially lead to novel cancer therapies

Nanomedicine strategy can help reduce heart attacks, strokes

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

New resource available to help older Chinese Americans better understand their healthcare needs

NASH patients more likely to have increased intestinal permeability, shows study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News